Skip to main
MCRB
MCRB logo

Seres Therapeutics (MCRB) Earnings Dates & Reports

Seres Therapeutics (MCRB) Most Recent Earnings

Report Date
Period EndingQ3 2025
Est. EPS$0.78
Actual EPS$0.94
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Seres Therapeutics (MCRB) Earnings per Share (EPS) History

Signup for full access
Browse free

Seres Therapeutics (MCRB) Latest Earnings

The value each MCRB share was expected to gain vs. the value each share gained.

Seres Therapeutics (MCRB) reported its most recent earnings on for Q3 2025, posting earnings per share (EPS) of $0.94. This exceeded analysts' expectations of $0.78 by 20.51%, marking a Beat.

For comparison, Seres Therapeutics reported EPS of -$6.60 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$1.92.

Seres Therapeutics (MCRB) Earnings History

Earnings
Est. EPSActual EPSSurprise
Q4 2025
-$1.92
Q3 2025
$0.78$0.94+20.51%
DeckReportListen
Q2 2025
-$2.45-$2.27-7.35%
DeckReportListen
Q1 2025
$1.60$3.75+134.37%
DeckReportListen
Q4 2024
-$4.00-$1.60-60.00%
DeckReportListen
View all

Seres Therapeutics (MCRB) Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Seres Therapeutics’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

Seres Therapeutics (MCRB) Earnings FAQs

Seres Therapeutics (MCRB) last reported earnings on Nov 5, 2025 for Q3 2025, posting an EPS of $0.94, which Beat the estimate of $0.78 by 20.51%.

For Q3 2025, Seres Therapeutics (MCRB) reported an EPS of $0.94, exceeding analysts' estimate of $0.78 by 20.51%.

For Q3 2025, Seres Therapeutics (MCRB) Beat expectations with an actual EPS of $0.94 vs. an estimated EPS of $0.78.

Following the last earnings report on Nov 5, 2025, Seres Therapeutics (MCRB)'s stock price moved — from — to —.

The next Seres Therapeutics (MCRB) earnings call is scheduled for Mar. 12, 2026, where executives will discuss financial results and outlook.

Seres Therapeutics (MCRB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.